- German Chancellor Olaf Scholz agreed to allow expatriates in China to use BioNTech SE BNTX made COVID-19 vaccine.
- BioNTech would be the first non-Chinese coronavirus vaccine in China, as Beijing has insisted on administering domestically produced vaccines.
- BioNTech partners on COVID vaccines with Pfizer Inc PFE in regions outside Greater China.
- Also Read: Pfizer/BioNTech Updated Omicron Adapted COVID-19 Vaccine Shows 4-Fold Higher Neutralizing Activity.
- In October, Moderna Inc's MRNA CEO Stephane Bancel said the company has talked with the Chinese government about supplying COVID-19 vaccines.
- But the company refused to hand over to China the core intellectual property related to developing its famed COVID-19 vaccine.
- A spokesperson for BioNTech told Reuters that vaccines for the Chinese market would be initially imported.
- While the COVID-19 shots are available in Hong Kong, Macau, and Taiwan, the regulatory review for mainland China has not been concluded.
- BioNTech has said that decision was up to Chinese regulators and did not give any reason for the delay.
- No other foreign-made COVID shot has gained access to mainland China's market.
- Price Action: BNTX shares are up 6.44% at $154.60 on the last check Friday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.